Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML

We conducted an open-label phase 1 study exploring the feasibility, safety, and biologic activity of epigenetic priming with decitabine before standard induction chemotherapy in patients with less-than-favorable risk of acute myelogenous leukemia (AML). We directly compared the clinical and DNA-hypo...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Scandura, Joseph M., Roboz, Gail J., Moh, Michelle, Morawa, Ewelina, Brenet, Fabienne, Bose, J. Robi, Villegas, Luis, Gergis, Usama S., Mayer, Sebastian A., Ippoliti, Cindy M., Curcio, Tania J., Ritchie, Ellen K., Feldman, Eric J.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Hematology 2011
Témata:
Clinical Trials and Observations
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3156041/
https://ncbi.nlm.nih.gov/pubmed/21613261
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2010-11-320093
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky